[go: up one dir, main page]

AU2003250958A8 - Use of cd152 for treating autoimmune diseases and inflammations - Google Patents

Use of cd152 for treating autoimmune diseases and inflammations

Info

Publication number
AU2003250958A8
AU2003250958A8 AU2003250958A AU2003250958A AU2003250958A8 AU 2003250958 A8 AU2003250958 A8 AU 2003250958A8 AU 2003250958 A AU2003250958 A AU 2003250958A AU 2003250958 A AU2003250958 A AU 2003250958A AU 2003250958 A8 AU2003250958 A8 AU 2003250958A8
Authority
AU
Australia
Prior art keywords
inflammations
autoimmune diseases
treating autoimmune
treating
diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003250958A
Other versions
AU2003250958A1 (en
Inventor
Monika Brunner-Weinzierl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Charite Universitaetsmedizin Berlin
Original Assignee
Charite Universitaetsmedizin Berlin
Universitatsklinikum Charite Berlin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Charite Universitaetsmedizin Berlin, Universitatsklinikum Charite Berlin filed Critical Charite Universitaetsmedizin Berlin
Publication of AU2003250958A8 publication Critical patent/AU2003250958A8/en
Publication of AU2003250958A1 publication Critical patent/AU2003250958A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2003250958A 2002-07-15 2003-07-15 Use of cd152 for treating autoimmune diseases and inflammations Abandoned AU2003250958A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10232697A DE10232697A1 (en) 2002-07-15 2002-07-15 Use of CD152 for the treatment of autoimmune diseases and inflammation
DE10232697.5 2002-07-15
PCT/EP2003/007665 WO2004006950A2 (en) 2002-07-15 2003-07-15 Use of cd152 for treating autoimmune diseases and inflammations

Publications (2)

Publication Number Publication Date
AU2003250958A8 true AU2003250958A8 (en) 2004-02-02
AU2003250958A1 AU2003250958A1 (en) 2004-02-02

Family

ID=30010180

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003250958A Abandoned AU2003250958A1 (en) 2002-07-15 2003-07-15 Use of cd152 for treating autoimmune diseases and inflammations

Country Status (3)

Country Link
AU (1) AU2003250958A1 (en)
DE (2) DE10232697A1 (en)
WO (1) WO2004006950A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8475790B2 (en) 2008-10-06 2013-07-02 Bristol-Myers Squibb Company Combination of CD137 antibody and CTLA-4 antibody for the treatment of proliferative diseases
EP2961416B1 (en) 2013-03-01 2019-11-13 The United States of America, as represented by The Secretary, Department of Health and Human Services Methods of producing enriched populations of tumor reactive t cells from peripheral blood

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4723782B2 (en) * 2000-01-03 2011-07-13 ティーアール アソシエイツ，エル．エル．シー． Novel chimeric protein and method of using the protein
EP3029062A1 (en) * 2000-05-26 2016-06-08 Bristol-Myers Squibb Company Soluble ctla4 mutant molecules and uses thereof
DE10038722C2 (en) * 2000-08-09 2002-07-25 Genethor Gmbh Procedure for the reduction of specific immune reactions

Also Published As

Publication number Publication date
DE10392933B4 (en) 2007-04-12
WO2004006950A3 (en) 2004-06-10
WO2004006950A2 (en) 2004-01-22
DE10392933D2 (en) 2005-07-14
AU2003250958A1 (en) 2004-02-02
DE10232697A1 (en) 2004-02-05

Similar Documents

Publication Publication Date Title
AU2003290548A1 (en) Prevention and treatment of synucleinopathic disease
EP1575480A4 (en) Compositions and methods for the treatment of immune related diseases
EP1578367A4 (en) Compositions and methods for the treatment of immune related diseases
EP1572116A4 (en) Compositions and methods for the treatment of immune related diseases
EP1576137A4 (en) Compositions and methods for the treatment of immune related diseases
AU2003239568A1 (en) Pyrrolotriazinone compounds and their use to treat diseases
AU2003278775A8 (en) Porifera-based therapeutic compositions for treating and preventing skin diseases
WO2004024097A9 (en) Compositions and methods for the treatment of immune related diseases
AU2003268531A8 (en) Materials and methods for treatment of allergic diseases
EP1531828A4 (en) Methods of treating bacterial infections and diseases associated therewith
HUP0401863A3 (en) Amino acid-copolymers for suppression of autoimmune diseases, and methods of use
AU2003298911A8 (en) Cyclosporins for the treatment of autoimmune diseases
IL166016A0 (en) Topical treatment of skin diseases
AU2003267532A1 (en) PEPTIDES AND PEPTIDE DERIVATIVES FOR THE TREATMENT OF Alpha-SYNUCLEIN-RELATED DISEASES
AU2003268295A8 (en) "diagnosis and treatment of infertility"
EP1581095A4 (en) Therapeutic methods for reducing fat deposition and treating associated conditions
GB0211295D0 (en) Treatment of pain
AU2003274963A1 (en) Mda-7 and free radicals in the treatment of cancer
AU2003206945A1 (en) Use of proteinase inhibitors in the treatment of autoimmune diseases
GB9927757D0 (en) Treatment of autoimmune diseases
AU2003259833A8 (en) Methods of treating neurodegenerative diseases
AU2003256447A1 (en) Treatment of autoimmune skin diseases
AU2003222250A1 (en) Treatment of autoimmune diseases
AU2003250958A8 (en) Use of cd152 for treating autoimmune diseases and inflammations
AU2003213898A1 (en) Prevention and treatment of mycoplasma-associated diseases

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase